Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

“GLP-1 Outcomes with people Using Psychoactive Substances (GLOW-UPS): a multi-stage, multi-site trial among persons involved in the criminal-legal system

Award Number: UM1DA064531
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2025
PERIOD OF PERFORMANCE END DATE: 05/31/2030

Group Awards By:

View Award Description

“GLP-1 Outcomes with people Using Psychoactive Substances (GLOW-UPS): a multi-stage, multi-site trial among persons involved in the criminal-legal system - PROJECT ABSTRACT This proposal is a large hybrid type 1 implementation effectiveness randomized controlled trial evaluating the comparative effectiveness of long-acting injectable buprenorphine (XRB) versus sublingual buprenorphine (SLB) among incarcerated adult volunteers with opioid use disorder (OUD) who are preparing for release. Both treatments are FDA-approved for OUD, and XRB offers the potential to improve adherence and reduce barriers to consistent medication use in correctional and community settings. The study will address the urgent need for high-quality data comparing these two buprenorphine formulations in corrections-to-community transitions, where individuals face heightened risks for overdose and poor treatment engagement. Participants will be recruited from three diverse Department of Corrections sites: Yale/Connecticut DOC, Dartmouth/New Hampshire DOC, and Friends Research Institute/Delaware DOC. The study team, which includes experienced PIs and academic partners, has long-standing collaborations with these sites, established protocols for XRB and SLB administration in correctional settings, and strong linkage systems to community care. A total of 300 adult participants with moderate-to-severe OUD will be randomized 1:1 to XRB or SLB prior to release, with the primary outcome being retention on buprenorphine at 12 weeks post-release. Secondary outcomes will include substance use measures, overdose events, qualitative feedback from participants, implementation feasibility, and cost analyses. This open-label, hybrid type 1 implementation-effectiveness trial leverages an innovative design to evaluate not only the clinical effectiveness of these medications but also the feasibility and relative costs of their implementation in correctional settings. As the first large multi-site trial of XRB versus SLB in this population, the study addresses key public health priorities and aligns with the NIH HEAL initiative’s goals to reduce opioid overdose deaths and improve treatment engagement during the critical post-release period. Findings from this study have the potential to inform best practices and expand the accessibility of medication for opioid use disorder (MOUD) in underserved carceral populations.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $1,374,439 )
2026	2026	NEW YORK UNIVERSITY	550 1ST AVE	NEW YORK	NY	10016	NEW YORK	USA	Drug Use and Addiction Research Programs	001	2	7/16/2026	NON-COMPETING CONTINUATION	$1,374,439
2026	2025	NEW YORK UNIVERSITY	550 1ST AVE	NEW YORK	NY	10016	NEW YORK	USA	Drug Use and Addiction Research Programs	000	1	3/11/2026	NEW	$0
														Subtotal = $1,374,439

Issue Date FY: 2025 ( Subtotal = $1,418,065 )
2025	2025	NEW YORK UNIVERSITY	550 1ST AVE	NEW YORK	NY	10016	NEW YORK	USA	Drug Use and Addiction Research Programs	000	1	9/9/2025	NEW	$1,418,065
														Subtotal = $1,418,065

Grand Total All Awards = $2,792,504

Top

All Categories

About

Search

Reports

Data Submission

Award Information

“GLP-1 Outcomes with people Using Psychoactive Substances (GLOW-UPS): a multi-stage, multi-site trial among persons involved in the criminal-legal system

Award Number: UM1DA064531

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2025

PERIOD OF PERFORMANCE END DATE: 05/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer